<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35393920</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation.</ArticleTitle>
        <Pagination>
          <StartPage>1164</StartPage>
          <EndPage>1175</EndPage>
          <MedlinePgn>1164-1175</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2058653</ELocationID>
        <Abstract>
          <AbstractText>Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic malignancies, and effective treatments are still lacking due to drug tolerance and tumor recurrence. In this study, we aimed to investigate the effects of sonodynamic therapy (SDT) on ovarian cancer and its potential mechanism. Folate receptor-targeted and ultrasound-responsive nanoparticles (NPs) were constructed using PLGA-PEG-FA (PLGA: poly (lactic-co-glycolic) acid, polyethylene glycol (PEG), FA: folate), the reactive oxygen species (ROS)-generating sonosensitizer IR780 and the oxygen-carrying material perfluorohexane (PFH), termed IRO@FA NPs. The antitumor effect of NPs triggered by ultrasound (US) was measured by an apoptosis assay in a C57/BL6 mouse model. Immunochemistry and flow cytometry were used to detect the proportion of CD3<sup>+</sup> T, CD4<sup>+</sup> T, CD8<sup>+</sup> T cells and activated dendritic cells (DCs) in spleens and tumor tissues to assess variation in the immune response. Moreover, endoplasmic reticulum (ER) stress and immunogenic cell death (ICD) markers (high mobility group protein box-1, ATP and calreticulin) were detected to identify potential mechanisms. The results showed that IRO@FA NP-mediated SDT promoted ID8 cell apoptosis both in vitro and in vivo. The densities of CD3<sup>+</sup> and CD8<sup>+</sup> T lymphocytes and inflammatory markers were upregulated in tumor tissues. IRO@FA NP-mediated SDT prompted DC maturation and T lymphocyte infiltration by inducing ID8 cell ICD.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yixuan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Long</LastName>
            <ForeName>Tengfei</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Dong</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yue</LastName>
            <ForeName>Song</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Ni</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Zhu</ForeName>
            <Initials>Z</Initials>
            <Identifier Source="ORCID">0000-0002-0610-499X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Gynecology and Obstetrics, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>3WJQ0SDW1A</RegistryNumber>
          <NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>935E97BOY8</RegistryNumber>
          <NameOfSubstance UI="D005492">Folic Acid</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005492" MajorTopicYN="N">Folic Acid</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000079527" MajorTopicYN="Y">Immunogenic Cell Death</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011092" MajorTopicYN="N">Polyethylene Glycols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="N">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ER stress</Keyword>
        <Keyword MajorTopicYN="N">Epithelial ovarian cancer</Keyword>
        <Keyword MajorTopicYN="N">immunogenic cell death</Keyword>
        <Keyword MajorTopicYN="N">sonodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">tumor microenvironment</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35393920</ArticleId>
        <ArticleId IdType="pmc">PMC9004507</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2058653</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abrahamse H, Hamblin MR. (2016). New photosensitizers for photodynamic therapy. Biochem J
473:347–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4811612</ArticleId>
            <ArticleId IdType="pubmed">26862179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alves CG, Lima-Sousa R, de Melo-Diogo D, et al.  (2018). IR780 based nanomaterials for cancer imaging and photothermal, photodynamic and combinatorial therapies. Int J Pharm
542:164–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29549013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaventura P, Shekarian T, Alcazer V, et al.  (2019). Cold Tumors: a therapeutic challenge for immunotherapy. Front Immunol
10:168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6376112</ArticleId>
            <ArticleId IdType="pubmed">30800125</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Cubillos-Ruiz JR. (2021). Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat Rev Cancer
21:71–88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7927882</ArticleId>
            <ArticleId IdType="pubmed">33214692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Y, Cheng H, Jiang C, et al.  (2015). Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. Nat Commun
6:8785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4659941</ArticleId>
            <ArticleId IdType="pubmed">26525216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiba S, Baghdadi M, Akiba H, et al.  (2012). Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol
13:832–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3622453</ArticleId>
            <ArticleId IdType="pubmed">22842346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng H, Zhou Z, Yang W, et al.  (2020). Endoplasmic reticulum targeting to amplify immunogenic cell death for cancer immunotherapy. Nano Lett
20:1928–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32073871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fucikova J, Coosemans A, Orsulic S, et al.  (2021). Immunological configuration of ovarian carcinoma: features and impact on disease outcome. J Immunother Cancer
9:1–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8515436</ArticleId>
            <ArticleId IdType="pubmed">34645669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Buque A, Kepp O, et al.  (2017). Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol
17:97–111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27748397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, Vitale I, Warren S, et al.  (2020). Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer
8:1–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7064135</ArticleId>
            <ArticleId IdType="pubmed">32209603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galon J, Bruni D. (2019). Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov
18:197–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30610226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi T, Rizzuto R, Hajnoczky G, Su TP. (2009). MAM: more than just a housekeeper. Trends Cell Biol
19:81–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2750097</ArticleId>
            <ArticleId IdType="pubmed">19144519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, Li Y, Du Y, et al.  (2019). Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Nat Commun
10:4871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6814770</ArticleId>
            <ArticleId IdType="pubmed">31653838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hwang WT, Adams SF, Tahirovic E, et al.  (2012). Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol
124:192–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3298445</ArticleId>
            <ArticleId IdType="pubmed">22040834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain RA. (2000). The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials
21:2475–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11055295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang C, Cheng H, Yuan A, et al.  (2015). Hydrophobic IR780 encapsulated in biodegradable human serum albumin nanoparticles for photothermal and photodynamic therapy. Acta Biomater
14:61–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25463484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kasikova L, Hensler M, Truxova I, et al.  (2019). Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J Immunother Cancer
7:312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6868694</ArticleId>
            <ArticleId IdType="pubmed">31747968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kepp O, Senovilla L, Vitale I, et al.  (2014). Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology
3:1–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4292729</ArticleId>
            <ArticleId IdType="pubmed">25941621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobel M, Madore J, Ramus SJ, et al.  (2014). Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An ovarian tumour tissue analysis consortium study. Br J Cancer
111:2297–307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4264456</ArticleId>
            <ArticleId IdType="pubmed">25349970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krysko DV, Garg AD, Kaczmarek A, et al.  (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer
12:860–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23151605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuroki L, Guntupalli SR. (2020). Treatment of epithelial ovarian cancer. BMJ
371:1–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33168565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwiatkowski S, Knap B, Przystupski D, et al.  (2018). Photodynamic therapy – mechanisms, photosensitizers and combinations. Biomed Pharmacother
106:1098–107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30119176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leitao MM, de Melo-Diogo D, Alves CG, et al.  (2020). Prototypic heptamethine cyanine incorporating nanomaterials for cancer phototheragnostic. Adv Healthc Mater
9:1–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31994354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lheureux S, Braunstein M, Oza AM. (2019). Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin
69:280–304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31099893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lheureux S, Gourley C, Vergote I, Oza AM. (2019). Epithelial ovarian cancer. Lancet
393:1240–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30910306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang S, Deng X, Ma P, et al.  (2020). Recent advances in nanomaterial-assisted combinational sonodynamic cancer therapy. Adv Mater
32:1–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33064322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang X, Ye X, Wang C, et al.  (2019). Photothermal cancer immunotherapy by erythrocyte membrane-coated black phosphorus formulation. J Control Release
296:150–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30682441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin YX, Wang Y, Ding J, et al.  (2021). Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models. Sci Transl Med
13:1–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8284983</ArticleId>
            <ArticleId IdType="pubmed">34162754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu J, Xu Y, Liu Z, et al.  (2019). A modified hydrophobic ion-pairing complex strategy for long-term peptide delivery with high drug encapsulation and reduced burst release from PLGA microspheres. Eur J Pharm Biopharm
144:217–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31563632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matulonis UA, Shapira-Frommer R, Santin AD, et al.  (2019). Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol
30:1080–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31046082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michaud M, Martins I, Sukkurwala AQ, et al.  (2011). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science
334:1573–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22174255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obeid M, Tesniere A, Ghiringhelli F, et al.  (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med
13:54–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17187072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pujade-Lauraine E, Fujiwara K, Ledermann JA, et al.  (2021). Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol
22:1034–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34143970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salmon H, Remark R, Gnjatic S, Merad M. (2019). Host tissue determinants of tumour immunity. Nat Rev Cancer
19:215–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7787168</ArticleId>
            <ArticleId IdType="pubmed">30867580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scaranti M, Cojocaru E, Banerjee S, Banerji U. (2020). Exploiting the folate receptor alpha in oncology. Nat Rev Clin Oncol
17:349–59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32152484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shu CA, Gainor JF, Awad MM, et al.  (2020). Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol
21:786–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32386568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Si Y, Yue J, Liu Z, et al.  (2021). Phase-transformation nanoparticle-mediated sonodynamic therapy: an effective modality to enhance anti-tumor immune response by inducing immunogenic cell death in breast cancer. Int J Nanomed
16:1913–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7943766</ArticleId>
            <ArticleId IdType="pubmed">33707946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Son S, Kim JH, Wang X, et al.  (2020). Multifunctional sonosensitizers in sonodynamic cancer therapy. Chem Soc Rev
49:3244–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32337527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tew WP, Lacchetti C, Ellis A, et al.  (2020). PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol
38:3468–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8942301</ArticleId>
            <ArticleId IdType="pubmed">32790492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torre LA, Trabert B, DeSantis CE, et al.  (2018). Ovarian cancer statistics, 2018. CA Cancer J Clin
68:284–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6621554</ArticleId>
            <ArticleId IdType="pubmed">29809280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Woude LL, Gorris MAJ, Halilovic A, et al.  (2017). Migrating into the tumor: a roadmap for T cells. Trends Cancer
3:797–808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29120755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, Guan R, Xie L, et al.  (2021). An ER-Targeting Iridium(III) complex that induces immunogenic cell death in non-small-cell lung cancer. Angew Chem Int Ed
60:4657–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33217194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Jiang Y, Wei D, et al.  (2021). Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance. Nat Biomed Eng
5:1048–58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8497438</ArticleId>
            <ArticleId IdType="pubmed">34045730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Wang B, Zhang L, et al.  (2020). Mitochondria-targeted nanospheres with deep tumor penetration for photo/starvation therapy. J Mater Chem B
8:7740–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32729606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye X, Liang X, Chen Q, et al.  (2019). Surgical tumor-derived personalized photothermal vaccine formulation for cancer immunotherapy. ACS Nano
13:2956–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30789699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Lu G, Wen X, et al.  (2020). Magnetic nanoparticles coated with polyphenols for spatio-temporally controlled cancer photothermal/immunotherapy. J Control Release
326:131–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32580043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang R, Zhang L, Ran H, et al.  (2020). A mitochondria-targeted anticancer nanoplatform with deep penetration for enhanced synergistic sonodynamic and starvation therapy. Biomater Sci
8:4581–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32691765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang T, Wu B, Akakuru OU, et al.  (2021). Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer. Cancer Lett
500:41–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33359275</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
